zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2011-8-1-5zdor-1058Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEОСТРЫЙ МИЕЛОИДНЫЙ ЛЕЙКОЗ: СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ (обзор литературы)ACUTE MYELOID LEUKEMIA: CURRENT APPROACHES TO DIAGNOSIS AND TREATMENT (literature review)ЛендинаИ. Ю.LendinaI. Yu.noemail@neicon.ruЗмачинскийВ. А.ZmachinskiyV. A.noemail@neicon.ruЦвиркоД. Г.TsvirkoD. G.noemail@neicon.ruУссА. Л.UssA. L.noemail@neicon.ruРеспубликанский научно-практический центр радиационной медицины и экологии человекаRepublican Research Center for Radiation Medicine and Human EcologyБелорусская медицинская академия последипломного образованияBelarussian Medical Academy of Postgraduate EducationРеспубликанский научно-практический центр гематологии и трансфузиологииRepublican Research Center for Hematology and Blood Transfusion9-я Городская клиническая больницаMunicipal Clinical Hospital No.9201128032011012934Copyright © Лендина И.Ю., Змачинский В.А., Цвирко Д.Г., Усс А.Л., 20112011Лендина И.Ю., Змачинский В.А., Цвирко Д.Г., Усс А.Л.Lendina I.Y., Zmachinskiy V.A., Tsvirko D.G., Uss A.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1058

В статье дается краткий обзор современных тенденций в лечении острого миелоидного лейкоза. Особое внимание уделяется определению факторов риска в дебюте заболевания и проведению риск-адаптированной терапии лейкозов.

The article gives a brief overview of current trends in the treatment for acute myeloid leukemia. The particular consideration is given to the definition of risk factors in the onset of the disease and of risk-adapted therapy of leukemia.

острый миелоидный лейкозфакторы прогнозавысокодозная терапиямолекулярно-генетические маркерытрансплантацияacute myeloid leukemiaprognosis factorshigh dose therapymolecular genetic markerstransplantationReferencesAge and acute myeloid leukemia / F. R. Appelbaum [et al.] // Blood. - 2006. - Vol. 107, № 9. - P. 3481-3485.Age and acute myeloid leukemia / F. R. Appelbaum [et al.] // Blood. - 2006. - Vol. 107, № 9. - P. 3481-3485.The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML, 10 trial. / D. Grimwade [et al.] // Blood. - 1998. - Vol. 92, № 7. - P. 2322-2333.The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML, 10 trial. / D. Grimwade [et al.] // Blood. - 1998. - Vol. 92, № 7. - P. 2322-2333.Mro´zek, K. Cytogenetics in acute leukaemia / K. Mro´zek, N. A. Heerema, C. D. Bloomfield // Blood Rev. - 2004. - Vol. 18, № 2. - P. 115-136.Mro´zek, K. Cytogenetics in acute leukaemia / K. Mro´zek, N. A. Heerema, C. D. Bloomfield // Blood Rev. - 2004. - Vol. 18, № 2. - P. 115-136.Mro´zek, K. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances / K. Mro´zek, H. Do¨hner, C. D. Bloomfield // Curr Opin Hematol. - 2007. - Vol. 14, № 2. - P. 106-114.Mro´zek, K. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances / K. Mro´zek, H. Do¨hner, C. D. Bloomfield // Curr Opin Hematol. - 2007. - Vol. 14, № 2. - P. 106-114.Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a Study of the AML Study Group Ulm / S. Frohling [et al.] // Blood. - 2002. - Vol. 100. - P. 4372-4380.Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a Study of the AML Study Group Ulm / S. Frohling [et al.] // Blood. - 2002. - Vol. 100. - P. 4372-4380.Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations / H. Do¨hner [et al.] // Blood. - 2005. - Vol. 106, № 12. - P. 3740-3746.Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations / H. Do¨hner [et al.] // Blood. - 2005. - Vol. 106, № 12. - P. 3740-3746.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis / C. Thiede [et al.] // Blood. - 2002. - Vol. 99, № 12. - P. 4326-4335.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis / C. Thiede [et al.] // Blood. - 2002. - Vol. 99, № 12. - P. 4326-4335.Favorable prognostic significance of CEBPAmutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) / C. Preudhomme [et al.] // Blood. - 2002. - Vol. 100, № 8. - P. 2717-2723.Favorable prognostic significance of CEBPAmutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) / C. Preudhomme [et al.] // Blood. - 2002. - Vol. 100, № 8. - P. 2717-2723.Wenberg, L. B. Acute myeloid leukemia and acute promyelocytic leukaemia / L. B. Wenberg, J. D. Griffin, M. S. Tallman // Hematology Am Soc Hematol Educ Program. - 2003. - P. 82-101.Wenberg, L. B. Acute myeloid leukemia and acute promyelocytic leukaemia / L. B. Wenberg, J. D. Griffin, M. S. Tallman // Hematology Am Soc Hematol Educ Program. - 2003. - P. 82-101.Aphase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study / W. R. Vogler [et al.] // J. Clin Oncol. - 1992. - Vol. 10, № 7. - P. 1103-1111.Aphase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study / W. R. Vogler [et al.] // J. Clin Oncol. - 1992. - Vol. 10, № 7. - P. 1103-1111.Anthracycline dose intensification in acute myeloid leukemia / H. F. [et al.] // Fernandez N Engl J Med. - 2009. - Vol. 361. - P. 1249-1259.Anthracycline dose intensification in acute myeloid leukemia / H. F. [et al.] // Fernandez N Engl J Med. - 2009. - Vol. 361. - P. 1249-1259.A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study / J. K. Weick [et al.] // Blood. - 1996. - Vol. 88, № 8. - P. 2841-2851.A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study / J. K. Weick [et al.] // Blood. - 1996. - Vol. 88, № 8. - P. 2841-2851.Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10) / I. M. Hann [et al.] // Blood. - 1997. - Vol. 89, № 7. - P. 2311-2318.Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10) / I. M. Hann [et al.] // Blood. - 1997. - Vol. 89, № 7. - P. 2311-2318.The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations / F. R. Appelbaum [et al.] // Br J Haematol. - 2006. - Vol. 135. - P. 165-173.The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations / F. R. Appelbaum [et al.] // Br J Haematol. - 2006. - Vol. 135. - P. 165-173.Varying intensity of postremission therapy in acute myeloid leukaemia / P. A. Cassileth [et al.] // Blood. - 1992. - Vol. 79. - P. 1924-1930.Varying intensity of postremission therapy in acute myeloid leukaemia / P. A. Cassileth [et al.] // Blood. - 1992. - Vol. 79. - P. 1924-1930.Intensive post-remission chemotherapy in adults with acute myeloid leukemia / R. J. Mayer [et al.] // N Engl J Med. - 1994. - Vol. 331, № 14. - P. 896-903.Intensive post-remission chemotherapy in adults with acute myeloid leukemia / R. J. Mayer [et al.] // N Engl J Med. - 1994. - Vol. 331, № 14. - P. 896-903.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group / E. Elonen [et al.] // Leukemia. - 1998. - Vol. 12. - P. 1041-1048.Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group / E. Elonen [et al.] // Leukemia. - 1998. - Vol. 12. - P. 1041-1048.Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group / B. Lowenberg [et al.] // J Clin Oncol. - 1998. - Vol. 16. - P. 872-881.Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group / B. Lowenberg [et al.] // J Clin Oncol. - 1998. - Vol. 16. - P. 872-881.Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial / R. F. Schlenk [et al.] // Leukemia. - 2003. - Vol. 17, № 8. - P. 1521-1528.Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial / R. F. Schlenk [et al.] // Leukemia. - 2003. - Vol. 17, № 8. - P. 1521-1528.Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study / S. P. Whitman [et al.] // Blood. - 2007. - Vol. 109, № 12. - P. 5164-5167.Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study / S. P. Whitman [et al.] // Blood. - 2007. - Vol. 109, № 12. - P. 5164-5167.Graft-versus-leukemia reactions after bone marrow transplantation / M. M. Horowitz [et al.] // Blood. - 1990. - Vol. 75, № 3. - P. 555-562.Graft-versus-leukemia reactions after bone marrow transplantation / M. M. Horowitz [et al.] // Blood. - 1990. - Vol. 75, № 3. - P. 555-562.Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identicalsibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? / J. J. Cornelissen [et al.] // Blood. - 2007. - Vol. 109, № 9. - P. 3658-3666.Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identicalsibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? / J. J. Cornelissen [et al.] // Blood. - 2007. - Vol. 109, № 9. - P. 3658-3666.Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358. - P. 1909-1918.Mutations and treatment outcome in cytogenetically normal acute myeloid leukaemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358. - P. 1909-1918.Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461 / J. C. Byrd [et al.] // J Clin Oncol. - 2004. - Vol. 22, № 6. - P. 1087-1094.Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461 / J. C. Byrd [et al.] // J Clin Oncol. - 2004. - Vol. 22, № 6. - P. 1087-1094.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia / R. F. Schlenk [et al.] // N Engl J Med. - 2008. - Vol. 358, № 18. - P. 1909-1918.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials / J. Koreth [et al.] // JAMA. - 2009. - Vol. 301, № 22. - P. 2349-2361.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials / J. Koreth [et al.] // JAMA. - 2009. - Vol. 301, № 22. - P. 2349-2361.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype / C. D. Bloomfield [et al.] // Cancer Res. - 1998. - Vol. 58, № 18. - P. 4173-4179.

The authors declare that there are no conflicts of interest present.